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Abstract
Background: T cells engineered to express chimeric antigen receptors (CARs) have established efficacy in the
treatment of B-cell malignancies, but their relevance in solid tumors remains undefined. Here we report results
of the first human trials of CAR-T cells in the treatment of solid tumors performed in the 1990s.
Methods: Patients with metastatic colorectal cancer (CRC) were treated in two phase 1 trials with first-generation
retroviral transduced CAR-T cells targeting tumor-associated glycoprotein (TAG)-72 and including a CD3-zeta
intracellular signaling domain (CART72 cells). In trial C-9701 and C-9702, CART72 cells were administered in
escalating doses up to 1010 total cells; in trial C-9701 CART72 cells were administered by intravenous infusion.
In trial C-9702, CART72 cells were administered via direct hepatic artery infusion in patients with colorectal liver
metastases. In both trials, a brief course of interferon-alpha (IFN-α) was given with each CART72 infusion to
upregulate expression of TAG-72.
Results: Fourteen patients were enrolled in C-9701 and nine in C-9702. CART72 manufacturing success rate was
100% with an average transduction efficiency of 38%. Ten patients were treated in CC-9701 and 6 in CC-9702.
Symptoms consistent with low-grade, cytokine release syndrome were observed in both trials without clear
evidence of on target/off tumor toxicity. Detectable, but mostly short-term (≤14 weeks), persistence of CART72
cells was observed in blood; one patient had CART72 cells detectable at 48 weeks. Trafficking to tumor tissues was
confirmed in a tumor biopsy from one of three patients. A subset of patients had 111Indium-labeled CART72 cells
injected, and trafficking could be detected to liver, but T cells appeared largely excluded from large metastatic
deposits. Tumor biomarkers carcinoembryonic antigen (CEA) and TAG-72 were measured in serum; there was a
precipitous decline of TAG-72, but not CEA, in some patients due to induction of an interfering antibody to the
TAG-72 binding domain of humanized CC49, reflecting an anti-CAR immune response. No radiologic tumor
responses were observed.
Conclusion: These findings demonstrate the relative safety of CART72 cells. The limited persistence supports the
incorporation of co-stimulatory domains in the CAR design and the use of fully human CAR constructs to mitigate
immunogenicity.
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One sentence summary
The authors describe the first human application of
autologous chimeric antigen receptor gene-modified T
cells targeting TAG-72 in the treatment of metastatic
colorectal cancer in two clinical trials.
Background
Adoptive transfer of T lymphocytes to target and treat
cancer is a field that has been evolving over the past
25 years. Initial efforts focused on isolation and expan-
sion of bulk T cells from peripheral blood or tumor infil-
trates, expansion ex vivo in the presence of stimulatory
cytokines and re-infusion into cancer patients [1]. These
efforts suffered from a lack of defined tumor specificity
and inability to track the fate of transferred cells. In the
1990s several new approaches were explored in parallel,
including genetic modification of T cells to express
known tumor-specific αβ T-cell receptors (αβ TCR) and
genetic engineering of T cells to express chimeric anti-
gen receptors (CARs) [2]. The latter approach employed
engineered CARs composed of an external antigen-
binding domain, typically a single-chain variable frag-
ment (scFv) targeting a tumor cell surface antigen,
linked to a transmembrane domain and an intracellular-
signaling domain, initially limited to the zeta (ζ) chain of
the TCR complex [3], and more recently including
additional signaling domains such as CD28 and 4-1BB
[4, 5]. Stable introduction of CARs into T cells has
focused on integrating viral vectors, including gamma
retroviruses [6] and lentiviruses [7], to enable in vivo ex-
pansion and persistence of gene-modified T cells. CAR-
T cell approaches offer the advantage of being human
leukocyte antigen unrestricted, but are limited to target-
ing molecules expressed on the extracellular tumor cell
surface.
Clinical investigation of CAR-T cells was undertaken
by Cell Genesys, Inc in the mid-1990s. The initial pro-
grams to enter the clinic focused on CD4-ζ-modified
CAR-T cells for treatment of human immunodeficiency
virus (HIV) infection [8]. A series of trials were con-
ducted starting with the treatment of HIV-infected dis-
cordant, syngeneic twin pairs in which CD8 T cells were
isolated from the uninfected twin, genetically modified
with the CD4-ζ CAR and re-infused into the HIV-
infected twin [9]. This was followed by a series of trials
of autologous CD4-ζ-modified CAR-T cells exploring
different CAR-T cell populations (mixed CD4 and CD8
T cells), optimized CAR-T cell ex vivo activation meth-
odologies utilizing immunomagnetic beads coated with
antibodies to CD3 and CD28 (CD3xCD28 beads) [10], in
vivo CAR-T cell treatment with and without interleukin-2
(IL-2), and treatment of both high-viral-burden HIV dis-
ease and minimal residual disease [11, 12]. Results from
these trials suggested that both ex vivo stimulation of
CAR-T cells with CD3xCD28 beads, and co-infusion of
CAR-modified CD4 and CD8 T cells were important for
long-term CAR-T cell persistence. No immunogenicity di-
rected against the native human CD4 protein extracellular
domain of the CD4-ζ CAR-T cells was observed and stable
persistence of infused CD4-ζ CAR-T cells was confirmed
for up to 10 years [13].
Concurrent with these trials in HIV infection, CAR-T cell
approaches targeting solid tumors were also pursued. T
cells expressing scFv-based CARs had demonstrated pre-
clinical activity against a variety of tumor targets [14–16].
The initial solid tumor-associated CAR target selected for
clinical application was TAG-72, an oncofetal mucin over-
expressed by most human epithelial adenocarcinomas,
with expression predominantly restricted to tumor cells
[17]. Prioritization of this target was also influenced by the
availability of a humanized antibody directed against TAG-
72 (huCC49) [18]. This huCC49 antibody was created by
grafting the complementarity-determining regions (CDR)
from the mouse CC49 (muCC49) antibody [19] onto a hu-
man framework. In addition, there existed a substantial
body of human safety data following administration of the
radiolabeled muCC49 in over 500 patients as a radiothera-
peutic [19–21] or radiodiagnostic tool [22]. Human anti-
mouse antibody (HAMA) responses associated with rapid
clearance of repeat doses of muCC49 were commonly ob-
served in these clinical trials. Use of a humanized scFv
CC49 CAR construct was deemed preferable to reduce the
risk of antibody induction against a murine scFv-based
CAR and potentially avoid immunogenic clearance of
TAG-72 targeted CAR-T cells.
A gamma-retroviral CAR construct was created con-
sisting of an extracellular domain composed of an scFv
derived from the huCC49 antibody linked to an IgG1
hinge, CH3 spacer, human CD4 transmembrane domain
and human CD3-ζ intracellular-signaling domain. This
vector was used to transduce CD4 and CD8 T cells using
the kat293 system [6] to create CC49-ζ-modified T cells
targeting TAG-72 [23]. CAR-T cells cultured in the pres-
ence of anti-CD3 (OKT3) plus IL-2 were shown to be-
come unresponsive to repeated stimulation through the
CC49-ζ CAR, whereas CAR-T cells cultured in the pres-
ence of CD3 and CD28 co-stimulation remained respon-
sive to repeated rounds of IL-2-induced proliferation.
CC49-ζ CAR-T cells secreted immune-reactive cytokines
(granulocyte-macrophage colony-stimulating factor, inter-
feron [IFN]-γ, tumor necrosis factor-α), proliferated, and
killed tumor cell lines as well as primary human colorectal
tumors expressing TAG-72 in vitro. CC49-ζ-modified
CD4 and CD8 T cells were capable of killing TAG-72-
expressing tumor cells with equivalent efficiency, but only
CD4 CAR-T cells were capable of IL-2 secretion and
proliferation following CD3 and CD28 co-stimulation,
suggesting that both populations were necessary for
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optimal in vivo proliferation and tumor killing [23]. Since
TAG-72 is secreted at different levels in the sera of
patients with advanced TAG-72-expressing tumors [24],
additional studies were performed that confirmed a lack
of inhibition of CC49-ζ CAR-T cell activity in the presence
of soluble TAG-72 protein. The activity of CC49-ζ CAR-T
cells was confirmed in vivo in a subcutaneous and dissem-
inated TAG-72-expressing tumor model [23].
Based on these encouraging preclinical data, two clin-
ical trials investigating CC49-ζ-expressing CD4 and CD8
CAR-T cells stimulated ex vivo with CD3xCD28 immu-
nomagnetic beads (hereafter referred to as CART72
cells) in patients with metastatic colorectal cancer (CRC)
were initiated in 1997. In the first trial (C-9701), patients
received escalating doses of CART72 cells administered
by intravenous (IV) infusion. Since the majority of the
blood supply to hepatic tumors is derived from the hep-
atic artery (HA), and to avoid potential trapping of
CART72 cells in the lung following IV administration, a
second trial (C-9702) was initiated in CRC patients with
liver metastases in which CART72 cells were infused
directly into the HA. Given the known heterogeneous
expression of TAG-72 in metastatic CRC and the ability
of interferons to upregulate expression of this antigen
[22], it was elected to co-administer IFN-α with each
dose of CART72 cells in both trials.
Given the current resurgence in interest in cancer di-
rected CAR-T cells, the now historical results of these
first two seminal clinical trials investigating first-
generation CAR-T cells in solid tumors are reported
here. These data provide important insights into some of
the challenges associated with the use of CAR-T cells to
treat solid tumors including tumor trafficking, CAR-T
cell persistence and anti-CAR immunogenicity.
Methods
Clinical trial design and planned treatments
Two open-label, phase 1 trials of CART72 cells in pa-
tients with metastatic CRC with liver metastases were
conducted between 1997 and 1998 under sponsorship by
Cell Genesys, Inc. CART72 cells were administered by
IV infusion in trial C-9701 and by intra-HA infusion in
trial C-9702. Eligible patients in both trials were adults
with metastatic CRC, including at least one liver metas-
tasis, with Karnofsky performance status of ≥ 80%, total
bilirubin < 3 times the upper limit of normal (ULN), and
transaminases < 5 times ULN. Additional eligibility in-
cluded expression of TAG-72 in ≥ 5% of tumor cells as
detected by immunohistochemistry with the CC49 anti-
body and serum TAG-72 levels < 500 U/mL. Patients
who received prior treatment with immunotherapy,
retroviral gene therapy or CC49 antibody were excluded.
The primary endpoint was safety and secondary end-
points included tumor response, TAG-72 upregulation
with IFN-α, CART72 persistence in blood and tumor,
and anti-CAR immunogenicity.
In the first trial (C-9701), six patients were scheduled
to receive intra-patient dose escalations of up to five in-
fusions of CART72 cells administered by IV infusion at
2-week intervals at two U.S. sites (UCSF and Stanford).
Planned doses included 108, 109, 1010, 1010 and 1010
total T cells with doses calculated based on total CD3 T
cells rather than transduced CART72 cells (Part A). This
was followed by four patients with three planned bi-
weekly IV infusions of 1010 total T cells (Part B). In trial
C-9702, six patients with CRC with liver metastases
were planned to receive intra-patient dose escalations of
109, 1010, 1010 and 1010 total T cells (doses also calcu-
lated based on total CD3 T cells rather than transduced
CART72 cells) administered via direct intra-HA infusion
at two U.S. sites (UCSF and Mary Crowley Cancer
Center). All patients in trial C-9702 were required to
have pre-existing percutaneous HA catheters and infu-
sion pumps in place from previous HA infusion chemo-
therapy protocols. All patients in both trials received
co-administration of IFN-α at a dose of 3 million units
(MU) by subcutaneous injection every other day for
four doses with each CART72 infusion in an effort to
upregulate expression of tumor-associated TAG-72. No
lymphodepleting chemotherapy was given prior to
CART72 administration.
Response and toxicity evaluation
Tumor response was measured using standard World
Health Organization (WHO) criteria; immune-related
response criteria had not yet been defined [25]. Safety
evaluation included standard monitoring using Common
Terminology Criteria for Adverse Events (CTCAE v2.0).
Adverse events were assessed as not related, possibly or
probably related to CART72 cells and/or IFN-α.
Preparation and testing of CC49-ζ Vector and CART72 Cells
Generation of the CC49-ζ retroviral vector has been de-
scribed previously [23]. The vector diagram is shown in
Fig. 1 and includes the huCC49 scFv linked to an IgG1
hinge and CH3 spacer, CD4 transmembrane domain and
CD3zeta signaling domain. The clinical grade, high titer
(>106 infectious units/mL), CC49-ζ retrovirus vector
used for ex vivo transduction of patient lymphocytes was
produced under Good Manufacturing Procedures at Cell
Genesys using the kat293 production cell line [6]. Mas-
ter cell bank and vector lots all tested negative for RCR
by supernatant amplification and co-cultivation on Mus
dunni cells [26]. Patient lymphapheresis was performed
at the participating clinical sites using an automated cell
separator (Cobe Spectra or CS-3000, Lakewood, CO,
USA) to achieve a minimum of 5 x 109 PBMCs in ap-
proximately 300 mL final volume. Apheresis products
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were shipped to Cell Genesys, Foster City, CA, USA,
and processed within 24 hours of receipt in a closed
system using Ficoll density gradient separation with a
Stericell device (Haemonetics, Braintree, MA, USA) to
remove residual red blood cells. Recovered PBMCs were
stimulated using immunomagnetic beads (Dynal, Oslo,
Norway) coated with anti-CD3 (OKT3) and anti-CD28
(monoclonal antibody 9.3), at a bead to cell ratio of 3:1,
in serum-free AIM-V medium (Gibco, Long Island, NY,
USA) and IL-2 (200 IU/mL; Chiron, Emeryville, CA,
USA). On Day 3, the beads were removed using a
Maxsep magnetic bead separator (Baxter, Roundlake, IL,
USA) and resuspended in AIM-V medium with IL-2
(200 IU/mL). Transduction with CC49-ζ retroviral
supernatant was performed on Days 5 and 7 in AIM-V
medium containing IL-2 and polybrene (Aldrich, St
Louis, MO, USA) using spinoculation at 800 x g for
30 minutes. After transduction, cells were expanded in
AIM-V medium with 200 IU/mL IL-2 in LIFECELL 3-L
bags (Baxter) until the target cell dose of > 4 x 1010 T
cells was obtained (Days 10–17). The final CART72 cell
products were cryopreserved in 50 mL sterile bags
containing 6 x 109 cells/bag in Plasmalyte-A (Baxter IV
Systems, Roundlake, IL, USA) with 10% dimethylsulfox-
ide (Sigma, St Louis, MO, USA), 1% dextran-40 (Baxter
IV Systems), and 5% human serum albumin (Alpha
Therapeutics, Los Angeles, CA, USA), and stored in li-
quid nitrogen. Final T-cell products were tested for via-
bility (by trypan blue exclusion), sterility, mycoplasma,
transduction efficiency by flow cytometry using anti-
idiotypic antibody (AI49-3; as described previously) [23],
RCR (co-cultivation on M. dunni cells) [26], and TAG-
72-specific 51Cr release cytolytic activity against 293 cells
(human embryonic kidney line) expressing TAG-72.
Phenotypic characterization was performed using anti-
bodies to CD3, CD4, CD8, CD28 (Coulter, Miami, FL,
USA), CD25 (Caltag, Burlingame, CA, USA), and
CD62L (Pharmingen, San Diego, CA, USA) by flow cy-
tometry. Mouse IgG control was used to determine
background staining and to set percent positive values
for each of the CD markers. Cryopreserved CART72
cells were thawed in a 37 °C water bath at the patient’s
bedside and infused directly through an IV or intra-HA
catheter over 5–10 minutes per bag. Infused CART72
cell dose was calculated based on total T cells rather
than transduced cells.
TAG-72 radioimmunoassay and immunogenicity
assessment
Monitoring of serum TAG-72 levels in treated patients
was originally planned using a CC49 capture RIA (Cen-
tocor 72–4 RIA). Following preliminary data suggestive
of artefactual drops in TAG-72, this assay was modified
to identify the presence of anti-idiotype antibody induc-
tion against the TAG-72 binding epitope of CC49.
Enzyme immunoassay plates were coated with two non-
competing murine TAG-72 binding antibodies (muCC49
and B72.3) at 10 μg/mL. Plates were blocked with Block-
ing Buffer (2% dry milk, PBS 0.05%, Tween20) and
washed with Wash Buffer (PBS 0.05%, Tween 20).
Normal Human Serum (NHS), patient serum with con-
firmed anti-idiotype reactivity to CC49, and the Blocking
Buffer were run as controls. An anti-idiotype blocking
antibody was not available for B72.3. Patient serum and
controls were diluted in the Blocking Buffer at 1:100,
1:1000 and 1:10,000, and were added to the plate. Plates
were washed and the detector antibody, polyclonal goat
anti-human Ig labeled with HRP diluted 1:5000 in PBS
was added. The plates were washed again and developed
using o-phenylene-diamine-dihydrochloride and optical
densities were measured at 490 nm. Positive anti-
idiotypic CC49 antibody activity was considered when
measurements were at least 1.8 times higher than NHS
at the same dilution.
Patient serum mixing studies and heat extraction
Patient serum was assessed for the presence of a TAG-
72 binding inhibitor in the Centocor 72.4 RIA. Sera were
analyzed prior to and following abrupt drops in mea-
sured TAG-72 levels (after repeated infusions of 1010
CART72 cells). Sera from the early time points were
mixed in equal volumes with NHS or with sera from the
late time points. Mixtures were mixed gently for 1 hour
at room temperature and then assayed in the TAG-72
capture RIA. Sample mixtures that showed a significant
Fig. 1 CC49-ζ vector diagram. A gamma retroviral CAR construct
consisting of a TAG-72 antigen-binding domain derived from the
humanized CC49 single-chain antibody linked to the CD3-ζ signaling
domain of the T-cell receptor via a human CD4 transmembrane
domain. CAR, chimeric antigen receptor; Fv, variable fragment; (G4-S)3,
(Gly4, Ser)3 peptide linker; IC, intracellular; TM, transmembrane; VH,
variable heavy chain; VL, variable light chain; γ1, immunoglobulin γ1
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reduction in titer when compared to NHS mixtures were
considered positive for a CC49 or TAG-72 inhibitor.
Heat treatment of serum was used to precipitate Ig in
conditions designed to not affect TAG-72 antigen
immunoactivity. Patient sera samples were diluted 1:3 in
0.01 M Bis Tris 0.15 M sodium chloride (pH 6.5).
Samples were split into two sets. One set was run as is
(diluted 1:3 with no heat treatment) and the other set
was boiled for 5 minutes at 90–100 °C. Both sample sets
were centrifuged at ~2000 g for 5 minutes. Supernatants
were tested in the TAG-72 capture RIA for quantifica-
tion of TAG-72.
CC49-ζ quantitative PCR assay
CART72 DNA levels in circulating PBMC and tumor
biopsy samples were measured using methods previ-
ously described [11] using primers specific for the
CC49-ζ construct. Planned time points included screen-
ing, Day 0 and 1 of each CART72 infusion, then every
2 weeks for the first 12 weeks and quarterly thereafter
for one year.
RCR Testing by PCR
Analysis for RCR was performed using Taqman PCR as
previously described [11]. RCR testing was performed on
released CART72 products and testing was planned on
blood samples from all enrolled patients at screening,
Week 4, every 3 months for the first year and annually
thereafter.
111Indium-labeled T-cell substudy
An Indium labeling substudy was performed in both tri-
als to explore trafficking of CART72 cells following IV
and intra-HA administration [27, 28]. The 111Indium la-
beling procedure was planned during one of the 1010
CART72 cell infusions. Cryopreserved final product
CART72 cells were aliquoted in bags containing 1–5 x
109 cells each, and only one bag was used for the 111In-
dium-labeling procedure. On the day of the scheduled
CART72 cell infusion, one bag of CART72 cells was
thawed at the clinical site, transferred on ice to the
Nuclear Medicine department at each institution, and la-
beled with 500–700 mCi of sterile 111Indium-oxyquino-
lone at room temperature for 10–20 minutes with gentle
rocking. A 5–10 mL aliquot of the labeled cell suspen-
sion was removed for cell counting, determination of cell
viability by trypan blue exclusion and labeling efficiency.
All manipulations during the cell labeling were carried
out under aseptic conditions using standard techniques
employed in routine 111Indium-labeling procedures.
Unlabeled CART72 cells were infused prior to the infu-
sion of 111Indium-labeled cells. Infusion occurred within
1–3 hours of the labeling procedure and receipt of the
unlabeled CART72 cells. Following infusion, the infusate
bag and tubing were returned to the Nuclear Medicine
department for appropriate disposal as radioactive waste.
111Indium has a radioactive half-life of 67 hours. The
estimated total body radiation exposure to the patient
was 0.31 rads/500 mCi of 111In. In addition, standard
Technicium aggragated albumin (99mTc-MAA) was in-
fused concurrent with 111Indium-labeled CART72 cells
to visualize vascularized liver and tumor tissue. Analog
and digital gamma camera images were obtained at 3–6
hours after infusion and again at 24, 48, 72 and 96 hours
post-infusion. At the discretion of the Principal Investi-
gator additional images were allowed on additional days
up to 15 days post-infusion.
Tumor biopsies
Optional percutaneous, ultrasound or computed tomography-
guided paired tumor biopsies were performed in eligible
patients at screening and various time points following
CART72 infusion. Percutaneous liver biopsies were
preferred, but biopsies of alternative accessible tumor
sites were allowed. Planned analyses included routine
histopathology, TAG-72 expression by immunohisto-
chemistry using CC49 antibody, and CART72 quantita-
tion by PCR.
Results
Patient characteristics and treatment
Between 1997 and 1998, two clinical trials investigating
CART72 cells were conducted in patients with meta-
static CRC at three clinical sites in the United States. All
enrolled patients underwent a lymphapheresis procedure
followed by ex vivo culture, retroviral gene modification
and expansion of autologous CART72 cells. CART72
cells were administered by IV infusion in trial C-9701
and by direct intra-HA infusion in trial C-9702. In both
trials, a brief course of IFN-α was given with each
CART72 infusion to upregulate expression of tumor-
associated TAG-72.
A total of 14 patients were enrolled in trial C-9701
and nine in trial C-9702, each at two clinical sites. In
trial C-9701, all 14 patients underwent lymphapheresis
and 10 (71%) initiated treatment with CART72 cells ad-
ministered by IV infusion (six in Part A; four in Part B).
Four patients were not treated because of patient with-
drawal (n = 2) or death due to progressive disease (n = 2)
prior to their first infusion. In trial C-9702, nine patients
were enrolled and six were treated with intra-HA infu-
sions of CART72 cells. Three patients were withdrawn
prior to their first infusion, most likely due to progres-
sive disease, but records are no longer available.
In trial C-9701, five of six patients from Part A com-
pleted all five planned IV infusions (108, 109, 1010, 1010,
1010 total T cells) and one withdrew after three infusions
(108, 109, 1010) because of disease progression. In Part B,
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two of four patients completed all three scheduled infu-
sions (1010 x 3) and two patients received two infusions
prior to withdrawal because of disease progression and
toxicity, respectively. In trial C-9702, five of six patients
received all four planned intra-HA infusions (109, 1010,
1010, 1010 total T cells); one patient received a 50% re-
duced dose of CART72 cells for the last two infusions
and one was withdrawn after the third infusion because
of toxicity. Based on the average transduction efficiency
of 38%, each 1010 total T cell dose contained approxi-
mately 3–4 x 109 CART72 cells.
Patients enrolled in trial C-9701 were mostly Cauca-
sian (one African American) of mixed gender (nine
male, five female) with a mean age of 56 years and good
performance status (Karnofsky score of ≥ 80%). Most
had extensive metastatic disease in liver, lung, bone and/
or spleen. All patients had been previously treated with
surgery and chemotherapy and three had received radio-
therapy. All patients enrolled in trial C-9702 had meta-
static disease in the liver and had failed prior HA
infusional chemotherapy and had HA infusion pumps
still in place.
Baseline levels of TAG-72 expression in tumor by
immunohistochemistry as well as serum levels of sol-
uble TAG-72 for patients in trial C-9701 are summa-
rized in Table 1. Expression levels were variable and
there was poor concordance between tumor expres-
sion of TAG-72 and serum levels of TAG-72.
CART72 cell manufacturing
CART72 cells were successfully processed and released
for infusion in all enrolled patients. Unselected autologous
T cells from lymphapheresis products were expanded ex
vivo after stimulation with anti-CD3 and anti-CD28 anti-
body conjugated beads (CD3xCD28 beads) in the pres-
ence of low-dose IL-2 (200 IU/mL) for an average of
13 days. T cells were transduced with a gamma-retroviral
vector containing the CC49-ζ CAR construct (Fig. 1). All
CART72 cell cultures were completed within 17 days,
reaching the minimum target dose of at least 3 x 1010 total
CD3 T cells by day 14 (Fig. 2). Average CART72 retroviral
transduction efficiency for CD3 T cells as measured by
flow cytometry was 38%. CART72 doses for infusion were
calculated based on total CD3 T cells rather than trans-
duced cells. The average composition of the final CART72
products was 54% CD4 and 41% CD8 T cells. Percentages
of final CART72 cell products expressing CD62L, CD28
and CD25 were 86%, 95% and 50%, respectively. Released
CART72 cell products showed potent and specific lysis of
cell lines expressing TAG-72 [24] and tested negative for
replication competent retroviruses (RCR).
Safety
Limited safety information is still available from both tri-
als due to incomplete access to historical trial records
and complete study reports. In trial C-9701, the most
frequently reported grade 1 – 2 adverse events attributed
to CART72 cells were chills (70%), fever, dizziness,
paresthesia (30% each), headache, tachycardia, myalgia
and hypoxia (20% each), all suggestive of low-grade cyto-
kine release syndrome (CRS) or IFN toxicity. Other grade
1 or 2 toxicities attributed to IFN-α included nausea
(50%), malaise (40%), flu syndrome, abdominal pain (30%
each), tachycardia, anorexia, dry mouth, vasodilation and
hypoxia (20% each). No grade 4 related adverse events
were reported. Grade 3 adverse events possibly related to
CART72 included retinal artery occlusion that developed
3 days following the second CART72 infusion (one
patient) and chills (one patient). There were no clinically
significant changes in laboratory values that were not
directly related to progression of disease. All patients
were treated as out-patients and no patients required
hospitalization for management of toxicities.
In trial C-9702, one patient (303D) developed fever, ab-
normal liver function tests, anemia and leukocytosis 6 days
following the second CART72 cell administration (first in-
fusion of 1010 cells) prompting a 4-day hospitalization. No
infection was identified and the patient did not develop
hypotension, hypoxia or require vasopressors. Symptoms
resolved spontaneously by 12 days post infusion and
laboratory abnormalities normalized to baseline levels by
22 days post infusion. The patient went on to receive three
additional CART72 cell infusions at a 50% dose reduction
Table 1 Baseline serum and tumor TAG-72 levels from trial C-9701






201A 5 2+ 9.4
202B 60 2+ 7.3
203C 95 2+ 91.3
204D 5 1+ 4.1
205E 80 2+ 8.2
206K 60 2+ 293.5
207L 70 2+ NA
101F 10 2+ 148.3
102G 5 1+ 6.4
103H 5 1+ 96.9
104I 5 1+ 13.6
105J 25 2+ 19.8
106M 80 2+ 187.4
107N 50 2+ NA
NA not available
Tumor TAG-72 levels were measured in archival or fresh tumors at baseline by
immunohistochemistry and quantified as percentage of cells staining positive
and staining intensity. Serum TAG-72 levels were measured using a CC49
capture radio-immunoassay
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of 5 x 109 cells per infusion. These subsequent infusions
were well tolerated, but the patient developed a recurrent
transient syndrome of fever, increased bilirubin and
anemia 2 months following the last infusion, which
responded to a short course of prednisone. A second
patient (305H) with a history of chronic atrial fibrillation
developed fever and rigors 2 hours following the third in-
fusion, complicated by rapid atrial fibrillation, transient
hypotension and mild congestive heart failure prompting
a 4 day hospitalization. Fevers resolved after 24 hours.
This patient also developed transient leukocytosis, anemia
and thrombocytopenia with maximal changes 24 –
48 hours post infusion followed by spontaneous recovery.
The fourth and final planned CART72 cell infusion was
not administered. Infusion-related toxicities that were not
dose-limiting were common and included fever, abdom-
inal pain, increased bilirubin, headache, nausea, vomiting
and anemia. Five of six patients completed all four
planned CART72 cell infusions and no patients died
within 30 days of CART72 treatment. RCR tests were
negative in all patients through 48 weeks of follow-up in
both trials.
Serum TAG-72 reductions and immunogenicity
Similar to the oncofetal antigen CEA, the TAG-72
mucin is shed into the serum by some proliferating CRC
cells [24]. Serum CEA and TAG-72 levels were, there-
fore, monitored in all patients as potential serum bio-
markers of tumor burden and response to CART72
treatment. These test results inadvertently led to the
identification of an induced anti-idiotype antibody re-
sponse directed the CC49-ζ CAR. Serum TAG-72 levels
increased acutely in most patients after initiation of IFN-
α, suggestive of an IFN-induced increase in TAG-72
expression and/or shedding from tumor or other tissues
(Fig. 3). In trial C-9701, seven of 8 evaluable patients
with measurable serum TAG-72 later demonstrated
abrupt reductions (>80%) in serum TAG-72 levels 5 to
9 weeks following the first cell infusion (Fig. 3a, b). The
remaining patient (105 J) showed a 25% decrease at
the last time point analyzed (Week 8). Of the two
evaluable patients in trial C-9702, both showed a
marked decrease in measured serum TAG-72 at Week
8 (85% and 60%) (Fig. 3c).
These large apparent reductions in TAG-72 initially
suggested a signal of antitumor efficacy. However all pa-
tients demonstrated concurrent radiologic evidence of
tumor progression. Furthermore, there were no consist-
ent reductions in CEA at the time of the measured
reductions in TAG-72 (Fig. 3d, e, f ).
The lack of concordance between TAG-72 levels, CEA
levels and tumor radiographic response, suggested that
the results from the TAG-72 RIA may have represented
an assay artifact. The commercial TAG-72 RIA kit used
the muCC49 capture antibody. This raised the possibility
of the development of an inhibitory antibody in patient
sera that blocked sera TAG-72 binding in the sandwich
assay. This hypothesis was confirmed by mixing post-
infusion sera from three patients who demonstrated
strong post-infusion drops in TAG-72 with TAG-72-
positive pre-infusion serum. This resulted in a 59–84%
decrease in the measured pre-infusion level of TAG-72
after mixing, consistent with the presence of an inhibi-
tory antibody in the post-infusion sera (data not shown).
In contrast, there was no decrease in pre-infusion TAG-
72 titer following mixing with normal human sera.
To confirm that the measured post-infusion reduc-
tions in TAG-72 were due to assay interference rather
Fig. 2 CART72 cell growth curves. Individual CART72 cell growth curves from trials C-9701 and C-9702 are shown. Lymphapheresis products were
depleted of red blood cells and stimulated with CD3xCD28 beads on Day 1 in the presence of IL-2 (200 IU/mL) with removal of beads on Day 3.
Spinoculation transduction with the CC49-ζ vector was performed on Days 5 and 7 followed by continued cell culture in serum-free media
supplemented with IL-2 (200 IU/mL). Minimum harvest criteria of 3 x 1010 total T cells was achieved on all lots by Day 17
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than true changes in TAG-72 levels, post-infusion sera
samples were heat-treated to denature serum antibodies
that might inhibit the detection of TAG-72. Seven of 8
evaluable patients in trial C-9701 and 2 of 2 evaluable
patients in trial C-9702, showed an increase in TAG-72
in post-infusion sera following heat treatment, with mea-
sured levels similar to the pre-infusion TAG-72 titer
(Table 2). These results were consistent with denatur-
ation of the inhibiting serum antibody.
Since muCC49 is the capture antibody in the TAG-72
RIA, possible inhibitors included a human anti-CC49
idiotype antibody that interfered with TAG-72 binding
or a human anti-TAG-72 idiotype antibody that inter-
fered with CC49 binding. To further elucidate the nature
of the induced inhibitor, pre- and post-infusion sera
were next assayed for the presence of anti-CC49 idiotype
antibodies using muCC49 as the capture protein. All
patients were negative for anti-CC49 reactivity in the
pre-infusion sera. In 8 of 10 patients in trial C-9701 and
3 of 3 patients in trial C-9702, post-infusion sera demon-
strated an increase in anti-CC49 antibodies, consistent
with the induction of an anti-CC49 idiotype antibody
(Table 2). To rule out the presence of a TAG-72 immune
complex binding to the muCC49 capture antibody, the
assay was repeated using B72.3 (another murine anti-
body recognizing a non-competing epitope of TAG-72)
as the capture protein. Seven of 7 patients tested nega-
tive in the B72.3 assay in both pre- and post-infusion
Fig. 3 Serum TAG-72 and CEA levels. Circulating sera levels of TAG-72 were measured by RIA in treated patients in: (a) Part A dose-escalation
phase of IV CART72 cells in trial C-9701; (b) Part B expansion phase of trial C-9701; and (c) Intra-HA CART72 cells in trial C-9702. Circulating sera
levels of CEA were measured in: (d) Part A of C-9701; (e) Part B of C-9701; and (f) C-9702. Seven of 8 evaluable patients treated with IV infusions
of CART72 cells later demonstrated abrupt reductions (>80%) in serum TAG-72 levels (a, b). Two of 2 evaluable patients who received CART72
cells via HA infusion showed a marked decrease in measured serum TAG-72 at Week 8 (85% and 60%, respectively) (c). No associated reductions
in sera CEA were observed, with an increase in the sera CEA levels over time observed in nine of 10 patients in trial C-9701 (d, e) and six of six
patients in C-9702 (f). CEA, carcinoembryonic antigen; HA, hepatic artery; IV, intravenous
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samples (data not shown). The results of these assays are
consistent with the induction of a CC49 anti-idiotype
antibody response targeting the TAG-72 binding domain
of the CC49-ζ CAR, with onset in a majority of treated
patients following the second or third infusion of 1010
CART72 cells.
CART72 persistence
CART72 cells were detected by DNA quantitative poly-
merase chain reaction (PCR) analysis in the blood of all
patients post-infusion (Fig. 4). In trial C-9701 (Part A)
peak levels occurred at weeks 4 to 6 following the first
infusion of 1010 CART72 cells and ranged from 220 to
31,418 copies/106 peripheral blood mononuclear cells
(PBMCs) (Fig. 4a). In trial C-9701 (Part B) peak levels
occurred at weeks 0 or 2 following the first or second in-
fusion of 1010 CART72 cells and ranged from 682 to
10,014 copies/106 PBMCs (Fig. 4b). Six of nine patients
showed peak levels representing greater than 0.1% of
PBMCs. Rapid clearance of CART72 cells from the
blood was observed following the second or third infu-
sion of 1010 CART72 cells in five of 10 patients. In three
patients, there was a 1- to 2-log decrease in the level of
CART72 cells following the second 1010 cell infusion,
and CART cells were detected intermittently at low
levels thereafter for at least 10 weeks following the first
infusion. Two patients were not evaluable for clearance
assessment because of short follow-up. In general,
clearance of CART72 cells coincided with the develop-
ment of the CC49-ζ idiotype antibody response.
In trial C-9702, all patients had detectable levels of
CART72 by DNA PCR in the blood following HA infu-
sion of 1010 CART72 cells (Fig. 4c). In contrast to trial
C-9701, peak levels occurred variably after the second,
third or fourth infusion of 1010 CART72 cells and
ranged from 1157 to 27,917 copies/106 PBMCs. Four of
six patients demonstrated clearance of CART72 cells by
Week 6 to 8 and a fifth by Week 14. The final patient
(303D) showed persistence of CART72 cells through
48 weeks of follow-up despite early detection of an anti-
idiotype response, with rising levels from Week 16 to 48,
Table 2 Anti-CC49-ζ immune responses in patients




C-9701 101 F 8.1 ++ ++
201A >2.6 +++ +++
202B 1.8 +++ +++
206 K 2.5 + +
105 J 1.2 + ++
106 M 2.5 + +
204D UND - -
102G >1.8 +++ ++
205E >1.0 ++ ++
C-9702 301B 1.3 + ++
303D >1.4 + ++
401A NA + -
NA, data not available, UND TAG-72 undetectable.
+, 1.5- to 3-fold increase; ++, 3.1- to 5-fold increase; +++, > 5-fold increase
TAG-72 was detected in sera samples from IV-infused (trial C-9701) and intra-
HA-infused (trial C-9702) CART72 cell patients following heat extraction of the
TAG-72 to dissociate the antigen from inhibitory antibodies. Antibodies against
the CC49 antibody were detected in all evaluable patients following infusion
with CART72 cells comparing the RIA titer post-infusion versus pre-infusion.
The detection of anti-CC49 antibodies coincided with the clearance of CART72
cells as measured by PCR
Fig. 4 CART72 persistence in blood. The CC49-ζ copy number
measured by quantitative PCR and expressed per 106 circulating
PBMCs over time is shown in: (a) Part A dose escalation phase of
CART72 cells administered by IV infusion in trial C-9701; (b) Part B
expansion phase of trial C-9701; and (c) CART72 cells administered
by HA infusion in trial C-9702. HA, hepatic artery; PBMC, peripheral
blood mononuclear cell; PCR, polymerase chain reaction
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possibly associated with loss in titer of the inhibitor. Of
note, this patient showed the greatest initial CART72 ex-
pansion (1369 to 27,917 copies/106 PBMCs from Day 1
to 15) associated with an acute febrile syndrome consist-
ent with cytokine release from Week 2 to 3, as well as a
recurrent syndrome consistent with cytokine release two
months following the final infusion at Week 16, associ-
ated with an increase in the level of CART72 in his
blood. In the face of evolving evidence of rapid CART72
clearance in most patients associated with generation of
an anti-CC49 idiotype response, a decision was made to
eliminate co-administration of IFN-α from the last two
patients (305H and 404I) based on the hypothesis that
IFN-α might have exacerbated immunogenicity of the
CART72 cells. Development of an anti-CC49 antibody
response associated with rapid CART72 clearance was
still observed at Weeks 4 and 8 in these last two patients
without IFN-α co-treatment.
Tumor trafficking of CART72 Cells
Three patients across both trials underwent paired
screening and on-treatment tumor biopsies to measure
TAG-72 expression levels and tumor trafficking of
CART72 cells (Table 3). In one patient in trial C-9701,
baseline expression of TAG-72 was evident in 5% of cells
in a rectal metastasis, as measured by immunohisto-
chemistry. A rectal tumor mass biopsied 3 days follow-
ing the third infusion of 1010 CART72 cells showed 10%
TAG-72 expression. Although CART72 cells were still
detectable in blood (1704 copies/106 PBMCs) at the time
of biopsy, CART72 cells were undetectable in the rectal
tumor. Two patients in trial C-9702 underwent on-
treatment biopsies of liver metastases 1 day and 2 weeks
following the fourth CART72 infusion. In the former,
CART72 cells were detectable in both the blood and
tumor tissue (1937 and 220 copies/106 PBMCs, respect-
ively) and the biopsied tumor showed an infiltrate of
CD3+ T cells. In contrast, no CART72 cells were de-
tected in blood or tumor of the second patient biopsied
at the later time point. Tumor TAG-72 expression levels
are not available on these latter two patients.
Four patients with radiologic liver metastases in trial
C-9701 were enrolled in a substudy to monitor the in
vivo trafficking of 111Indium-labeled CART72 cells based
on experience with this technique to monitor trafficking
of adoptively transferred tumor-infiltrating lymphocytes
[24, 25]. Trafficking of 111Indium-labeled CART72 cells
was compared to tumor uptake of infused technetium
albumin aggregated particles (99mTc-MAA), which
visualize vascularized tumor tissue. In general, CART72
cells were observed to cluster at the perimeter of large
tumor masses without evidence of deep tumor penetra-
tion, whereas 99mTc-MAA distributed uniformly
throughout the metastatic tumors consistent with ad-
equate vascularization of the tumor masses (Fig. 5).
Clinical outcome
No radiologic tumor responses were observed in either
trial during the planned 12-week monitoring period. The
best response in both trials was progressive disease. One
of 10 patients (207 L) in trial C-9701 demonstrated a >
50% decrease in CEA and 2 additional patients (201A,
205E) demonstrated transient reductions in CEA of un-
clear significance (Fig. 3d, e). One of 6 patients (303D)
in C-9702 demonstrated two transient decreases in CEA
levels concordant with clinical febrile syndromes sug-
gestive of CRS (Fig. 3f ). Patients were not routinely
monitored for possible late tumor regressions following
early radiologic progression as has been reported in more
recent trials of cancer immunotherapies [25]. One patient
(303D) treated with intra-HA infusion of CART72 cells
remained alive with persistently detectable and rising
levels of CART72 cells in blood 48 weeks following initial
treatment. This patient demonstrated the greatest acute
CART72 expansion, had symptoms consistent with CRS
on two separate occasions, both of which were associated
with transient drops in serum CEA levels, and had the
longest duration of CART72 persistence (48+ weeks).
Discussion
This report describes the results of a pair of important
early clinical trials in the field of CAR-T cells targeting
solid tumors. These trials preceded the next clinical trial
of CAR-T cells in a solid tumor indication by more than
5 years [29]. Initially dismissed as negative studies, the
lessons learned retain value and are especially relevant





Timing of biopsy CC49-ζ by PCR (copies/106 cells)
Tumor Blood
303D HA Liver Day of 4th infusion 220 1937
301B HA Liver 2 weeks post 4th infusion <50 <117
201A IV Rectum Day of 5th infusion <50 1704
HA hepatic artery, IV intravenous, PCR polymerase chain reaction
Levels of CC49-ζ modified CART72 cells were measured by PCR in tumor biopsies taken at variable time points post-CART72 infusion in three patients. CC49-ζ
levels in biopsied tumor tissue were compared to levels in blood at corresponding time points. Patients 303D and 301B were treated in trial C-9702 and patient
201A was treated in trial C-9701
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now given the resurgence of interest in this field.
Important observations from these trials include: 1) the
robustness and reproducibility of autologous CD4 and
CD8 T cell transduction and expansion using a gamma-
retroviral vector and co-stimulation with CD3xCD28
immunomagnetic beads; 2) persistence of CART72 cells
in blood (up to 48 weeks in one subject) with evidence
of clinical symptoms consistent with mild to moderate
CRS, most pronounced in patients with the highest
levels of CART72 cells in blood; 3) trafficking of
CART72 cells, at least to some degree, to tumor tissues;
and 4) most importantly, the immunogenicity of the
CART72 cells, despite the use of a human chimeric
CC49 scFv in the CAR construct, that was associated
with rapid clearance of subsequent CART72 infusions in
most patients.
The CART72 manufacturing process used in this study
was nearly identical to that previously described for the
production of CD4-ζ CAR-T cells from HIV-infected
patients [11, 12] using CD3xCD28 bead co-stimulation
in the presence of low-dose IL-2 (200 IU/mL). The effi-
ciency and consistency of ex vivo T cell transduction
and expansion from CRC patients, reaching 4–5 x 1010
total T cells within 17 days, was remarkably similar to
that reported for manufacturing of CD4-ζ CAR-T cells
from HIV-infected patients and from healthy donors
[9]. High transduction efficiencies of approximately
40% using the kat293 high-titer gamma-retroviral vec-
tor were reported for both autologous CAR-T products
and yielded mixed populations of gene-modified CD4
and CD8 T cells. This high level of transduction effi-
ciency eliminated the need for post-transduction purifi-
cation to enrich for transduced cells, thus significantly
simplifying the manufacturing process. Phenotypic
analysis revealed a high proportion of activated T cells
expressing CD62L and CD28, with intermediate expres-
sion of CD25, and resulted in engineered T cells resist-
ant to activation induced cell death upon TAG-72
engagement.
In distinct contrast to the clinical experience with
CD4-ζ CAR-T cells, which persisted at relatively stable
levels in the blood of treated HIV-infected patients for
up to 10 years [11–13], rapid clearance of CART72 cells
from the blood following repeated infusions of 1010 cells
was observed in most patients treated in these cancer
studies. This clearance was associated with the develop-
ment of an anti-idiotype immune response directed
against the huCC49 scFv, initially identified via interfer-
ence with measurement of sera TAG-72 levels in a CC49
capture RIA. Fortuitously, in retrospect, the TAG-72
RIA assay served as a robust assay to measure the onset
and kinetics of induction of this CC49-ζ anti-idiotype
antibody response. These results provide a cautionary
note to others in the field of CAR-T cell therapies seek-
ing to target tumors other than malignant B cells or
plasma cells with scFv-based CAR constructs. However,
CC49 may have particularly immunogenic antigen-
binding epitopes. Following initiation of these CART72
trials, it was reported that anti-idiotype responses were
part of the HAMA response in 54% of the patients
treated with muCC49 [30]. Subsequent efforts led to the
creation of next-generation huCC49 antibodies with only
the specificity-determining residues of the mouse TAG-
72 binding epitopes grafted onto the frameworks of the
human antibody [31]. One such variant, V59, was shown
not to react with the anti-idiotype present in the sera of
patients treated with muCC49. This next-generation
huCC49 construct might be a better choice for future
CAR-T cell programs targeting TAG-72. Alternatively,
CAR-T cell constructs using fully human extracellular
antibody domains should be considered. Finally, patients
in these CART72 trials did not receive lymphodepleting
chemotherapy prior to infusion of CART72 cells, as the
beneficial effect of these conditioning regimens on the in
vivo proliferation and clinical activity of adoptively
transferred tumor-specific T cells had not yet been re-
ported [32]. It is possible that lymphodepleting chemo-
therapy (eg, fludarabine and cyclophosphamide), now
Fig. 5 Tumor trafficking of 111In-labeled CART72 cells. 111In-labeled CART72 cells were infused in four patients and compared to infusion of 99mTc-
MAA and imaging was performed at 3–96 hours post-infusion. Representative images from one patient at 24 hours post infusion of 1010 CART72
cells are notable for decreased penetration of 111In-labeled CART72 cells (b) into the center of a liver metastases compared with well distributed
dissemination of 99mTc-MAA (a). 111In, 111Indium; 99mTc-MAA, technetium albumin aggregated particles
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routinely administered with second-generation CAR-T
cell therapies, will further reduce the risk of developing
anti-CAR immune responses.
Despite the induction of an anti-CAR immune re-
sponse and more rapid clearance of CART72 cells in
these trials than observed with CD4-ζ CAR-T cells, some
encouraging preliminary signals of in vivo tumor traf-
ficking and biologic activity were observed. Short-term
detection of CART72 cells in blood was observed in
most patients. Several patients treated with direct HA
infusion of CART72 cells developed a constellation of
clinical symptoms, which, in retrospect, was consistent
with CRS. One patient with the highest peak levels of
CART72 cells in blood developed symptoms consistent
with CRS associated with transient drops in serum CEA
levels, and showed rising levels of CART72 cells at
48 weeks post-first infusion. In one of three patients,
CART72 cells were detected in a biopsy of a liver metasta-
sis post-infusion, confirming trafficking of cells to tumor
tissue. However, 111Indium-labeling of infused CART72
cells suggested incomplete penetration of CART72 cells
into the center of large tumor masses in several patients
analyzed. Future CAR-T cell programs in advanced solid
tumors may benefit from incorporating strategies to en-
hance homing and tumor penetration of infused CAR-T
cells, or focus on patients with minimal tumor burden
following cytoreductive therapies. In addition, second-
generation CAR T-cell approaches incorporating add-
itional T-cell signaling domains (eg, CD28, 4-1BB) have
been shown to enhance in vivo CAR-T cell expansion and
persistence, and have resulted in dramatic clinical re-
sponses in B-cell malignancies [33–37]. Preclinical data
also support the use of ICOS-ζ intracellular domains to
promote bipolar helper T (Th)1/Th17 cell differentiation,
resulting in improved effector function and in vivo persist-
ence [38]. One or more of these additional T-cell co-
stimulatory domains will likely be incorporated into all
future solid tumor CAR-T cell programs.
An additional challenge to the development of next-
generation CAR-T cells targeting solid tumors remains
the limited number of truly tumor-restricted cell-surface
targets, posing a clinical risk for on-target/off-tumor
toxicity [39]. No serious on-target/off-tumor toxicity was
observed in these CART72 trials suggesting that TAG-
72 remains a reasonable CAR target for next-generation
solid tumor approaches. However, greater in vivo prolif-
eration, effector function or persistence of second- and
third-generation CAR-T cells may uncover toxicities not
observed in these first-generation trials. Incorporation of
titratable control systems to regulate and/or eradicate
CAR-T cells if unacceptable toxicity arises should be
considered [40, 41]. Heterogeneous tumor-associated
surface antigen expression in most solid tumors also re-
mains a vexing problem. Tumor-associated TAG-72
expression is non-uniform and there were insufficient
data from these CART72 trials to know whether co-
administration of IFN-α resulted in sufficient TAG-72
upregulation to avoid antigen-loss escape. Targeting of
multiple tumor antigens concurrently with multi-specific
CAR-T cells is of interest for future solid tumor CAR-T
programs [5, 42, 43].
Conclusions
The field of CAR-T cells has established clear clinical
proof-of-concept for treatment of B-cell malignancies.
These belated clinical results from the first CAR-T cell
trials conducted in a solid tumor indication provide
valuable insights to guide the design of next-generation
CAR-T cell approaches tackling the more complex
tumor microenvironment of solid tumors.
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